Marksans Pharma's UK Subsidiary Receives Marketing Authorization for Levonorgestrel 1.5 mg Tablets

Marksans Pharma Limited’s wholly owned subsidiary in UK, Relonchem Limited, has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA. Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred. Marksans Pharma Limited is headquartered at Mumbai, India and is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti- allergies. The company is marketing these products globally.